Fournier gangrene

1. SGLT2 inhibitors raise the risk of Fournier gangrene in humans (OR 10.33, 95% CI: 4.59-23.27, p = 0.001).

   “Fournier's gangrene, although rare, occurred significantly more often (10 vs. 14 cases; OR 10.33, 95% CI: 4.59-23.27, p = 0.001)”

   Humansheart failure without diabetes, advanced kidney/liver disease, cancer, or immunodeficiency5-year follow-up

   Increasing Risk of Fournier’s Gangrene and Other Rare Genital Infections in Heart Failure Patients with and without Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): A Multicenter Cohort Study

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on SGLT2 inhibitors